ADPT President and COO Julie Rubinstein Sells $288K of Stock

Inside Julie Rubinstein's ADPT Trade

Julie Rubinstein, President and Chief Operating Officer of Adaptive Biotechnologies Corporation, sold 11,881 shares of ADPT stock on October 16, 2026. According to a Form 4 filing with the SEC, the shares were sold at an average price of $24.24, bringing the total transaction value to $288,010.89. The sale was executed under a pre-arranged Rule 10b5-1 plan. Following the transaction, Rubinstein directly holds 377,802 shares, representing a 3.05% reduction in her stake.

Other Institutional Activity in Adaptive Biotechnologies Corporation

Large funds continue to adjust their positions in ADPT. Viking Global Investors, L.P. held steady with 29,993,708 shares valued at about $720,448,879. Meanwhile, Shaw D.E. & Co., Inc. grew its holdings by 2,660,252 shares, ending with 4,625,859 shares worth about $111,113,135, which is a 135.3% increase. Westfield Capital Management Co LP reduced its position by 1,168,845 shares, ending with 4,267,645 shares worth about $102,508,834, representing a 21.5% decrease.

Adaptive Biotechnologies Corporation Stock Down 5.4%

Adaptive Biotechnologies recently traded around $24.19 as of October 17, 2026. The stock sits below its 50-day moving average and 21.3% below its 52-week high of $30.74, while trading well above its 52-week low of $12.00.

Recent Earnings

Adaptive Biotechnologies reported trailing-twelve-month revenue of $308,080,992 with an earnings per share of -$0.41. The company has a net profit margin of -20.7% and a return on equity of -38.8%. Its next earnings release is scheduled for November 4, 2026.

Insider Buying and Selling at Adaptive Biotechnologies Corporation

This sale marks another recent move by Rubinstein, following three similar planned transactions earlier in October 2026 where she sold identical blocks of 11,881 shares on October 9, October 12, and October 13. Earlier in the year, Chief Commercial Officer of Immune Medicine Sharon Benzeno purchased 103,295 shares on June 29, 2026, at an average price of $7.28 for a total value of $751,605.41.

Analysts Set New Price Targets

Wall Street firms have updated their outlooks on ADPT in recent weeks. On September 22, 2026, BTIG maintained its Buy rating and raised its target from $25.00 to $34.00. Goldman Sachs initiated coverage with a Buy rating and a $35.00 price target on September 29, 2026. Guggenheim maintained a Buy rating on October 1, 2026, lifting its target from $25.00 to $32.00. TD Cowen maintained a Buy rating and raised its target from $28.00 to $32.00 on October 13, 2026. On the same day, Morgan Stanley maintained its Equal-Weight rating while boosting its target from $22.00 to $27.00. The stock carries a consensus strong buy rating with a mean price target of $29.81 across eight analyst opinions.

About Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation builds an immune medicine platform focused on diagnosing and treating various diseases. The company uses proprietary chemistry, computational biology, and machine learning to decode the adaptive immune system and generate clinical immunomics data. This platform supports diagnostic and therapeutic developments in healthcare.

Bottom Line

Investors are keeping an eye on Adaptive Biotechnologies as it approaches its next financial results announcement on November 4, 2026. Insider transactions under pre-arranged plans offer a window into executive stock management, though they do not necessarily signal shifts in broader business momentum.